

2023-2024

IMPACT REPORT

A UNIQUE APPROACH TO ADVANCING CANCER RESEARCH



TOGETHER, WE OUTSMART CANCER

“We have a deep conviction that it is through research that we will continue to make life-changing, significant progress, giving hope to those affected by cancer.”

Manon Pepin
President and chief executive officer

SUMMARY

This Impact Report presents the activities and financial information of the Cancer Research Society from September 1st, 2023 to August 31st, 2024.

Message from the President and CEO, and the Chairman of the Board of Directors	4
State of Cancer in Canada	6
Team	7
Board of Directors	8
Scientific Advisory Committee	9
Management team	10
Research	11
Covering The Research Spectrum	13
Evaluation Committees	14
Annual Programs	15
Targeted Programs	17
Clinical Trials	18
Partners	20
Research Funding	21
Signature Events	22
2023 Cyclo-Golf Classic	23
2023 Accords Célestes	23
2023 Read for the Cure	24
2024 Urban BBQ	24
2023 Challenge Against Cancer Program	25
Financial Information	26
Planned Giving	29
Corporate Donations	31
Our Ambition for the Future	36

MESSAGE FROM THE PRESIDENT AND CEO, AND THE CHAIRMAN OF THE BOARD OF DIRECTORS

It is with great pleasure that we present the Impact Report of the Cancer Research Society (CRS) for the 2023-2024 fiscal year. The past year has once again been marked by remarkable achievements, allowing us, for the third consecutive year, to fund a record number of cancer research projects across the country.

Thanks to our efforts, **260 innovative research projects** received a total investment of **\$15.3 million**, significantly contributing to the fight against this disease, which remains the leading cause of death in Canada.

A Unique Approach to Advancing Cancer Research

Since 1945, CRS has stood out as one of the few Canadian organizations entirely dedicated to scientific research on all types of cancer. This is the very essence of our mission.

Over the decades, research has led to significant advancements that have improved survival rates for those affected. These breakthroughs

are the result of discoveries in the areas of prevention, more effective and less invasive detection techniques, as well as more targeted treatments. These advancements are our *raison d'être* and motivate us to pursue our mission every day.

This is why we play a leading role among researchers across Canada who are in constant need of funding to explore innovative concepts in the fight against cancer. The large number of applications we receive for our various programs underscores the urgent need to financially support these projects.

Year after year, CRS maintains its course while continually raising the bar. For example, we have increased the amount of grants awarded to researchers as well as the number of projects we fund. This exceptional commitment enriches Canada's cancer research ecosystem.

Our organization also stands out through the diversity of its programs, which meet the urgent needs of researchers at various stages of their careers. Through our various initiatives, we offer unique support, whether through doctoral awards, postdoctoral awards, or operating grants for established researchers. This

unparalleled support fosters continuity and growth in scientific research, ensuring that these researchers continue their academic careers in Canada.

Since last year, we have also strengthened our partnerships with other foundations and organizations to co-fund research projects. These collaborations maximize the impact of our investments and bring real benefits to the scientific community and patients.

Our Pillars

Our financial resources rely entirely on the generosity of our donors and partners. This drives us to constantly innovate in raising awareness and engaging as many stakeholders as possible. Partnerships are at the heart of our business model, allowing us to join forces with other organizations to leverage our reach. We are proud of our achievements over the past year, some of which are detailed in this impact report.

We are committed to maximizing the impact of every donation we receive, regardless of its amount, and to ensuring it has an impact. A heartfelt thank you to the thousands of donors who, through their support, are truly making a difference, and to our loyal partners.

We also want to express our deep gratitude to the members of our Board of Directors and our Scientific Advisory Committee. Their commitment, expertise, and dedication play a key role in guiding the strategic decisions of our organization. We are privileged to have their unwavering support.

In conclusion, we would like to warmly thank the staff of CRS. Their daily dedication to the cause of cancer research makes all the difference.

Cancer affects each of us, in one way or another. We reiterate our commitment to reducing its impact on our lives, thanks to all of you!

Enjoy your reading!



Manon Pepin

President & Chief
Executive Officer



Christian M. Paupe

Chairman of the Board
of Directors

STATE OF CANCER IN CANADA

Cancer remains the leading cause of death in Canada, affecting nearly one in two Canadians over their lifetime. Nearly **45% of Canadians** are expected to be diagnosed with cancer in their lifetime, representing approximately **247,100 new cases** in 2024.

Reference: Projected estimates of cancer in Canada in 2024 – Canadian Medical Association Journal, July 2, 2024

Most Common Cancers

The most frequently diagnosed types of cancer are expected to be:



Impact on Mortality

Cancer also remains the most common cause of death in Canada, with

88,100
expected deaths in 2024.

Progress Despite Rising Cases

Although the number of cancer cases in 2024 is expected to increase compared to previous years, the overall incidence of cancer and cancer mortality continue to decline. These reductions are likely due to ongoing efforts across the entire spectrum of cancer control and improvements in prevention, detection, and treatment made possible in part by research funding. That's why we are 100% dedicated to it.





TEAM

BOARD OF DIRECTORS

The CRS team is supported by a dedicated Board of Directors composed of experts from various regions across Canada.

Their knowledge and guidance inform our decision-making, ensuring that our efforts lead to success.

We extend our warmest thanks for their voluntary involvement in advancing cancer research.



**Chairman
of the Board**

Christian M. Paupe
Corporate Director



**Vice-president
and Secretary**

Heidi Lange, CRHA
Partner, Richter



Treasurer

Marie Valcourt, CPA
Partner
KPMG LLP

Board Members



Peter Clair
Director and Market
Lead, National
Accounts, Québec,
Scotiabank



Ghassan Deko
Director Corporate
Client Groupe –
Finance RBC



Benoît Durocher
Executive Vice-
President & Chief
Economic Strategist
Addenda Capital Inc.



**Alexandra T.
Greenhill, MD**
Founder, CEO and
Chief Medical Officer
Careteam
Technologies



Carson Loh
Regional Vice
President, North Shore
and Tri-Cities Market
RBC Royal Bank
(British Columbia)



Annie Marsolais
Chief Marketing Officer
Business Development
Bank of Canada (BDC)



Peter McCarthy
Vice Chair
BMO Insurance



**François
Painchaud**
Lawyer and Partner
ROBIC



Sean O'Brien
Executive
Vice-President,
Operational
Efficiency
iA Financial Group



**George
Zogopoulos,
MD, PhD,
FRCS(C), FACS**
Associate Professor
of Surgery and
Oncology at McGill
University
Hepato-Pancreato-
Biliary and
Transplant Surgeon
McGill University
Health Center

SCIENTIFIC ADVISORY COMMITTEE

To ensure our decisions regarding our scientific programs and competitions are always guided towards achieving the greatest impact, CRS relies on the expertise of a highly dedicated Scientific Advisory Committee. Composed of cancer research experts from diverse backgrounds, these members volunteer their time to support our mission.

We are very privileged that they have chosen our organization, and we sincerely thank them for their contribution.



President

Dr. Mark Basik, MD

Herbert Black Professor of Surgical Oncology, McGill University
Surgical Oncologist, Lady Davis Institute, Jewish General Hospital (JGH)
Head of the Cancer Genomics and Translational Research laboratory

Committee Members



Jacques Côté, PhD

Full Professor, Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval
Canada Research Chair in Chromatin Biology and Molecular Epigenetics
Fellow of the Royal Society of Canada (FRSC)



Rama Khokha, PhD

Senior Scientist at the Princess Margaret Cancer Centre (PM), University Health Network
Full Professor in the Department of Medical Biophysics, cross appointed to the Department of Laboratory Medicine and Pathobiology, University of Toronto



Dr. Don Morris, MD, PhD

Head, Department of Oncology, Cumming School of Medicine, University of Calgary
Head, Clinical Department of Oncology, Calgary Zone, Alberta Health Services
Professor of Oncology and Medicine, University of Calgary
Medical Director of the Tom Baker Cancer Centre
Medical Lead of the New Calgary Cancer Centre
Associate Senior Medical Director of Cancer Care Alberta, Alberta Health Services



Christopher Ong, PhD

Associate Professor, Department of Urologic Sciences, University of British Columbia
Senior Research Scientist, Vancouver Prostate Centre



Marie-Élise Parent, PhD

Professor at Institut national de la recherche scientifique (INRS), Armand-Frappier Santé Biotechnologie Research Centre
Adjunct Professor in the School of Public Health, Department of Social and Preventive Medicine, Université de Montréal
Elected Member of Scientific Council, International Agency for Research on Cancer, World Health Organization



Lynne-Marie Postovit, PhD

Professor and Department Head, Biomedical and Molecular Sciences, Queen's University

MANAGEMENT TEAM

The Cancer Research Society's management team collaborates closely with approximately thirty dedicated professionals across CRS.

Together, they work to maximize the impact of funds invested in research by coordinating strategic, financial, and operational efforts.



Manon Pepin
President and
Chief Executive Officer



Tina Mignacca, CPA
Director, Finance
and Administration



Dajan O'Donnell, PhD
Director, Scientific
Affairs and Partnerships



Koudjo Oni, MBA
Director, Revenue
Development



Catherine Paquette
Director, Communications
and Marketing



RESEARCH

Once again, this year, CRS has reaffirmed its unwavering commitment to research on all types of cancer. Thanks to the generosity of our partners and donors, we are supporting a record number of **260 projects**, representing a total investment of **\$15.3 million**.


By exceeding its goals once again, CRS strengthens its role as a leader in cancer research funding in Canada, benefiting all those affected by this disease.

A 3rd


consecutive

year of records

Number of grants



Investments in Research (in millions of dollars)



COVERING THE RESEARCH SPECTRUM

At CRS, we firmly believe that research is the key to outsmart cancer. Whether it's exploring the most complex biological mechanisms or developing therapies for patients, every discovery contributes to advancing our mission. Our approach is to support a wide range of research projects to stimulate innovation and foster effective solutions.

We support
all stages of
cancer research:

This is achieved
through our
various programs:



Fundamental Research

focuses on understanding the biological and molecular mechanisms of cancer, exploring the processes that lead to the onset and progression of various forms of the disease.

Annual programs provide crucial support for fundamental research projects



Translational Research

aims to transform discoveries into concrete solutions, such as developing new drugs or screening techniques, to accelerate the application of scientific innovations for the benefit of patients.

Targeted programs address specific scientific issues, with a particular emphasis on translational and pre-clinical research



Clinical Research

involves evaluating the efficacy and safety of new treatments by testing them directly on patients. It is crucial for validating innovative therapies before their integration into medical practice.

Support of **clinical trials** led by researchers



EVALUATION COMMITTEES

Evaluating Research Excellence

CRS is dedicated to funding high-quality research into all types of cancer, in order to better prevent, detect and treat this disease. We are committed to ensure that every donation received has a significant impact on cancer research.

CRS implements a meticulous peer-review process for each program to determine which research projects will receive funding. Each year, nearly 100 researchers, clinicians, and doctors rigorously and voluntarily evaluate the submitted grant applications. This thorough process ensures that funded research projects are carefully selected based on their relevance, feasibility, and potential to advance cancer knowledge.

ANNUAL PROGRAMS

Driving Cancer Advancements

To effectively support cancer research in Canada, CRS has established several annual grant programs. These programs aim to fund promising projects and help the entire scientific community overcome the funding challenges it faces. They provide financial support for research projects conducted by scientists at all career stages - students, postdoctoral fellows, and established researchers - united by a common goal: the fight against cancer.

Researchers **Operating Grants / \$125,000 over 2 years**

83
new grants!

The Operating Grants program is the cornerstone of our support for research on all types of cancer. By funding a diverse range of projects among the most promising in Canada, we maximize our impact in advancing knowledge in cancer prevention, detection, and treatment. Currently, 173 ongoing grants are supporting innovative projects that are driving these advancements forward.

[TO LEARN MORE, CLICK HERE](#)

Postdoctoral fellows **Next Generation of Scientists Awards / \$175,000 over 3 years**

5
new grants!

The Next Generation of Scientists Awards program, unique in Canada, supports the most promising postdoctoral fellows in establishing their laboratories and leading their own cancer research projects. Serving as a true springboard for launching their careers, this program actively contributes to the training of the next generation of cancer researchers in Canada. With awards spanning 3 years, 13 recipients are currently benefiting from this crucial support at this important stage of their careers.

[TO LEARN MORE, CLICK HERE](#)

Doctoral students **Doctoral Research Awards / \$70,000 over 2 years**

FIRST EDITION!
21
scholarships awarded!

The Doctoral Research Awards program aims to support and encourage doctoral students conducting cancer research at Canadian universities. The scholarships provided allow them to focus exclusively on their research, offering essential financial support for their scientific training. Launched for the first time this year, the program received an impressive 170 applications from students across Canada!

[TO LEARN MORE, CLICK HERE](#)

Together, these programs play a central role in driving new cancer discoveries and developing the next generation of researchers in Canada.

Empowering Research: Essential Funding Increases

The recent increases in the stipend of our Operating Grants and Next Generation of Scientists Awards reflect our determination to addressing the urgent needs of the research community. Each grant in these two programs has been raised by \$5,000 compared to last year, an essential step to ensure researchers have the necessary resources to carry out their work effectively. This increase not only recognizes the rising costs of research but also provides essential support for advancing innovative cancer studies. We are pleased to announce that this increase will be renewed for coming year!



TARGETED PROGRAMS

Creating New Initiatives to Outsmart Cancer

Through partnerships, major donations, and various initiatives, CRS occasionally launches targeted programs to provide grants in specific research areas, such as certain rare or particular types of cancer.



Grants for Ovarian Cancer Treatments: Bridging the Gap

Each year, approximately 3,100 Canadian women are diagnosed with ovarian cancer. Unfortunately, current treatments are often insufficient. This year, CRS partnered with Ovarian Cancer Canada to support translational research projects aimed at prolonging survival and improving quality of life for women affected by this disease. An investment of **\$1.8 million** has been allocated to three projects, offering new hope for patients.



Translational Research Grants for Lung Cancer

In Canada, lung cancer remains the leading cause of cancer-related deaths, yet it is one of the most underfunded areas of research. To address this challenge, CRS launched this targeted program that provides a total of **\$2 million** in funding for four translational research projects. This significant investment is made possible thanks to the exceptional generosity of donors, including the Gosselin Family Foundation, the Molson Foundation, and the George Papadopoulos Memorial Fund.



First International Partnership

This year, CRS established a groundbreaking international partnership with the British charity Worldwide Cancer Research (WCR). If a Canadian cancer research project is selected in WCR's 2024 grants competition, it will receive a remarkable grant of **\$460,000** over three years, co-funded by our two organizations. This partnership opens new international funding opportunities for Canadian researchers, allowing them to conduct fundamental or translational research targeting cancer prevention, diagnosis, and treatment.



CLINICAL TRIALS

Innovating to Save Lives

While maintaining our focus on fundamental research, we have recently paved the way for researcher-led clinical trial funding. These trials test new treatments or interventions directly on patients, evaluating their effectiveness and safety before they become publicly available. By supporting these projects, we aim to provide new prospects for improved recovery outcomes and enhanced quality of life for cancer patients.

Currently, we are supporting **6 clinical trials**, each focused on different types of cancers. To give you a clearer overview, here is an update on our two most recently funded clinical trials.

Blood Cancer Clinical Trial

The GLIDE project, led by Dr. Denis-Claude Roy, is developing a cutting-edge technology to enhance bone marrow transplants for blood cancer treatment. This precision medicine approach aims to select and activate donor cells capable of recognizing and eliminating specifically cancer cells, multiply them in the laboratory, and then inject these cells into the patient. The goal is to reduce complications and improve treatment effectiveness. CRS is supporting this project with **\$1.5 million** in funding, thanks to the generosity of Mr. Herbert Black and Mr. Ronald Black.

Clinical Trial for Brain Cancer in Children

This project focuses on evaluating a care protocol to reduce radiation exposure in young children with rare embryonal brain tumours. Led by Dr. Annie Huang, it involves the direct and precise administration of chemotherapy and additional treatments into the fluid surrounding the brain and spinal cord. This protocol offers hope for improving treatments for these children. The project is funded with **\$600,000** over four years through the DECRYPT grant, supported by CRS and six other partner organizations.



PARTNERS

CRS would like to express its heartfelt gratitude to the exceptional partners who have contributed to our research funding efforts. Thanks to their generosity and unwavering support, we have been able to fund more projects and launch new initiatives to support cancer research.

These collaborations amplify our overall impact in the fight against the disease.

Partners



Funds

- › Andy and Léna Chabot Fund
- › Aristotle Fund
- › Cancer Research Society's Environment-Cancer™ Fund, funded in part by Read for the Cure
- › Charlotte Légaré Memorial Fund
- › Connie Lynn and Kenneth George Fenney Fund
- › Herbert James Davies Memorial Fund
- › Suzanne and Louis Daubois Memorial Fund
- › Ken & Anne-Marie Lucas Memorial Grant
- › Jeux Saint-Lambert of the Cancer Research Society
- › Marche du rêve of the Cancer Research Society
- › Rob Lutterman Memorial Fund
- › Michael O'Gallagher Memorial Fund


RESEARCH FUNDING

Annual Programs




Operating Grants

173



Scholarships for
undergraduate students

4



Next Generation
of Scientists Awards

13



Doctoral Research Awards

21

Targeted Programs



Upcycle:
Drug Repurposing

2



Metastatic Breast Cancer

2



Ovarian Cancer

12



Brain Cancer

2



Blood Cancers

25



Clinical Trials

6

Total Number of Research
Projects Funded
260

Investment:
\$15.3M
(Includes administration costs)



SIGNATURE EVENTS

Each year, CRS organizes signature events, made possible by the indispensable support of valuable partners and dedicated organizing committees. These events bring together hundreds of passionate donors, united by ambitious and meaningful activities that directly contribute to funding cancer research. These events are not only opportunities to raise funds but also powerful moments of solidarity and commitment to a common cause.



2023 CYCLO-GOLF CLASSIC

Over \$180,000

For its 29th edition, the Classic took place in two cities: Montreal and Sherbrooke. Thanks to the participation of numerous cyclists, golfers, and walkers, this event was a tremendous success, raising a net amount of \$183,500 to support Canada's most promising cancer research projects.

[READ THE ARTICLE](#)

Scotiabank.

BMO Insurance



2023 ACCORDS CÉLESTES

Over \$300,000

The 6th edition of the Accords Célestes event, presented by MTY Group, broke records by raising a net amount of \$303,000! In support of cancer research, this unforgettable evening offered the perfect blend of flavors and melodies to hundreds of guests.

[READ THE ARTICLE](#)



COGECO MEDIA



2023 READ FOR THE CURE

Over \$85,000

The 16th edition of Read for the Cure took place in Vancouver, Toronto, and Ottawa. This literary event, known for its deep commitment to cancer research, brought together nearly 1,000 literature enthusiasts in support of the CRS's Environment-Cancer Fund™.

[READ THE ARTICLE](#)



Penguin
Random House
Canada



2024 URBAN BBQ

\$790,000

For its 10th anniversary, the Urban BBQ set a new record by raising an impressive net amount of \$790,000! This exceptional and festive event brought together over 1,000 guests, all united by a passion to support cancer research and drive the cause forward.

[READ THE ARTICLE](#)





CHALLENGE

AGAINST CANCER

Our Challenge Against Cancer program raised more than \$250,000 net in 2024. Since its inception, the program has raised over \$4.9 million and continues to offer participants a unique opportunity to explore the world, push their limits, and raise funds to advance cancer research.

This year, our participants had the opportunity to explore exceptional destinations such as Cambodia, Morocco, Italy, and Newfoundland.

Congratulations to all the participants for their outstanding commitment and determination. Their dedication is both inspiring and crucial in outsmarting cancer.



Contact Amérique
Voyage



André Robitaille in Cambodia

In March 2024, our spokesperson André Robitaille took on his second Challenge Against Cancer, this time in Cambodia. Driven by his commitment to support cancer research and honor those affected by the disease, André continues to tackle these challenges with passion and determination. Catch the highlights of his inspiring journey in this captivating video.

[WATCH THE VIDEO](#) (only in French)

A photograph of a group of people in a meeting. A woman with dark hair, wearing a light blue blazer, is smiling broadly and pointing her right index finger towards a document on a table. To her left, a man with a white beard and a white shirt is also looking towards the document. In the foreground, the back of a person's head and shoulder are visible, looking towards the meeting. The table has several documents, a black folder, and a pen. A large red curved line is drawn across the top right of the image.

FINANCIAL INFORMATION

CRS ensures rigorous financial management, despite challenges such as an uncertain economic climate. Thanks to well-thought-out strategic decisions by our team and the support of dedicated partners, our organization maintains **sound financial stability** while **maximizing the impact of every dollar invested** in research. Our financial resources rely exclusively on the generosity of our donors and partners.

SUMMARY OF REVENUES AND EXPENSES

From September 1st, 2023
to August 31st, 2024

\$32 MILLION
RESEARCH PROGRAM
COMMITMENTS SPREAD OVER
SEVERAL YEARS UP TO 2029

(in thousands of dollars)

REVENUES

	2024 Total	2023 Total
Annual campaigns	24,789	23,653
Major donations and planned giving	2,730	2,782
Benefit events and others	3,477	4,042
Research contributions	2,367	2,239
Investment income, realized	3,320	2,095
Investment income, unrealized	4,048	2,597
	40,731	37,408

EXPENDITURES

Annual campaigns	13,755	12,694
Major donations and planned giving	228	206
Benefit events and others	1,798	1,837
Administration	1,566	1,512
Depreciation of fixed assets	54	53
	17,401	16,302

SURPLUS AVAILABLE FOR RESEARCH

GRANTS AND FELLOWSHIPS (including related expenses)

EXCESS OF REVENUES OVER EXPENDITURES

	23,330	21,106
	15,332	13,283
	7,998	7,823

SUMMARY OF THE STATEMENT OF FINANCIAL CONDITION

On August 31, 2024

(in thousands of dollars)

ASSETS

	2024 Total	2023 Total
Cash	2,196	6,714
Accounts receivable	104	61
Prepaid expenses	227	215
Other current assets	83	118
Short-term investments	7,000	5,000
	9,610	12,108

Investments	59,779	49,023
Fixed assets	214	242
	69,603	61,373

LIABILITIES

Accounts payable and accrued liabilities	2,071	2,067
Deferred contributions – short term	926	682
	2,997	2,749

Lease inducement	58	75
	3,055	2,824

FUND BALANCES

Allocated funds	6,460	5,668
General funds	60,088	52,881
	66,548	58,549
	69,603	61,373



PLANNED GIVING

Once again this year, many individuals have chosen to support CRS through a legacy gift. We want to express our sincere gratitude for this act of great generosity, filled with hope. Their contribution plays a vital role in funding innovative research while leaving a valuable legacy for future generations.

To learn more, please visit our website CancerResearchSociety.ca or contact:

Catherine Jetté

Manager of Major and Planned Giving

Phone: 514 861-9227 ext. 248

Toll-free number: 1 866 343-2262 ext. 248

Email: cjette@src-crs.ca

Mary Bagg	Dr. David Robert Greatrix	Norma McLean Charitable Fund
Céline Bédard	Guy Harvey	Olav Nummelin
Céline Chainé	Terence Morton Heaps	Helen Florence Oram
Denis Charest	Suzanne Jenkins	Cécile Pépin
Georges Cousineau	Nancy Ann Kingston	Hélène Pomerleau
Adele Maria Jutta Dalton	John Lennon	Frank J. Reilly
Jon Dlusy	Yves Lizotte	Hélène Sabourin
Catherine Dumas	Georges MacDougall	Catharina Van Doorn Vink
Louise Ferragne	Maud and Christina Duncan Foundation	Stephane Vernet

A photograph of a diverse group of people at an event, many of whom are clapping. In the foreground, a man with short dark hair and a beard is seen in profile, wearing a plaid shirt. In the background, a woman with long blonde hair is visible. The scene is lit with warm, golden light, suggesting an indoor event with large windows. A thick red curved line runs across the bottom of the image.

CORPORATE DONATIONS

A huge thank you to our precious corporate partners for your generosity and commitment!

These organizations that join their efforts and resources with ours allow us to carry out our mission successfully.

\$100,000 and up

- › BMO Bank of Montreal/BMO Global Asset Management/ BMO Life Insurance /BMO Private Wealth – The Patry Group BMO Mastercard
- › Famille Léon and Diane Gosselin Foundation
- › George Papadopoulos Memorial Fund
- › Herbert and Ronald Black
- › RBC Royal Bank/RBC Dominion Securities/ RBC Capital Markets
- › Vachon Group / Prud'Homme Langlois Group/Gilles E. Richer Financial Group/ Marchand Filiatrault Team/ Joey Rizzuto/ Charles Lasnier/Kent Group/ PH & N Investment Services
- › The Molson Foundation

\$50,000 to \$99,999

- › Econo-Malls
- › iA Global Asset Management/ iA Financial Group
- › Innovairre Studios Inc.
- › Maud and Christina Duncan Charitable Foundation

\$25,000 to \$49,999

- › Scotiabank
- › Cogeco
- › Bergeron-Jetté Foundation
- › MTY Group
- › Power Corporation of Canada
- › Raymond Chabot Grant Thornton

\$10,000 to \$24,999

- › 2701545 Canada Inc.
- › Arbell Electronics
- › AtkinsRéalisis Canada Inc.
- › Benny & Co.

- › BLP Lawyers
- › Brain Finance
- › Business Development Bank of Canada
- › Canaan Management
- › Celebrations Group
- › CN Community Fund
- › Corporation BCF Inc.
- › Crowe BGK
- › Deschênes Group Inc.
- › Ernst & Young
- › Fasken Martineau DuMoulin
- › Freedom International Brokerage Company
- › Hardyenvie Foundation
- › Horno Leasing Ltd
- › Jarislowsky Fraser Ltd
- › Luc Maurice Real Estate Management
- › McCarthy Tétrault
- › National Bank Financial
- › Omni Brokerage Group / Geloso
- › Port of Montreal

- › Robic
- › SAQ
- › SFL Wealth Management
- › Spiegel Sohmer
- › TD/TD Securities /TD Asset Management
- › Techbanx
- › The Cole Foundation
- › Tidan Inc.
- › Unifood

\$5,000 to \$9,999

- › 144781 Canada Inc.
- › 15122708 Canada Inc.
- › 500 Place D'Armes Inc.
- › 9129-0429 Québec Inc.
- › 9284 0354 Québec Inc.
- › 9384-6780 Québec Inc./ AM Déjeuner et Dîner
- › Accord Financial
- › Addenda Capital
- › Agences Réal Demers Inc.
- › Air Canada

- | | | | |
|-------------------------------|------------------------------|---------------------------|-----------------------------|
| Alfid Real Estate Services | Genesis Holding LTD. | Saputo Inc. | AdMare BioInnovations |
| ALRE Properties | Gilbert, Séguin Lawyers | Soeurs Missionnaires | AGF Investments Inc. |
| Alstom | Gowling WLG (Canada) | de Notre-Dame des Anges | Agropur |
| Apollo Microwaves Ltd. | LLP/'Gowling WLG | Succès Scolaire | Akkus International |
| Assistenza International | Groupe Mach Inc. | The Charles Norcliffe | Aliments Pro-Marque |
| Association of Registered | IMKT Direct Solutions Corp. | Baker & Thelma Scott | American Society |
| Interior Designers of Ontario | Jean Coutu Group | Baker Foundation | of Plumbing |
| Au Vieux Duluth | Jones Day | The Tenaquip Foundation | Au Noir |
| Candex Solutions | L.R.D. Financing Inc. | The William and Nona | Avila Investments Ltd |
| Canada Inc. | La Cordée Macap Inc. | Heaslip Foundation | Axion 50 Plus |
| Carbonleo | La fromagerie Hamel | Torys | Bastium Construction |
| CBRE Capital Canada Inc. | Laurentide Controls | Yves Légaré Funeral Homes | BCF |
| CGC Charitable Foundation | Levy Salis | | Beauward Real Estate |
| Chassis d'auto ideale | Mackenzie Investments | \$1,000 to \$4,999 | Bédard Ressources Inc. |
| Montreal centre Inc. | Markham Waterloo | 115533 Canada Inc. | Bell Canada |
| CN Employees' and | Mennonite Conference | 154867 Canada Inc. | BellatRx Inc. |
| Pensioners' Community Fund | Relief Account | 1800 McGill College | Big Bang ERP |
| Cogir Real Estate | Medisca | Management Inc. | Big Bend Farming Co. LTD. |
| Connor, Clark & Lunn | Metro Richelieu Inc. | 1832 Asset Management LP | BIOQuébec |
| Financial Group | Michael Allan Johnson | 2356268 Ontario Limited | Blake, Cassels & |
| Cours de Bresoles Inc. | Foundation | 2990199 Canada Inc. | Graydon LLP |
| Cox Family of Brownlee | Miller Thomson | 3Mmm | Borden Ladner Gervais LLP |
| SK Foundation | MSC Group | 9014-4304 Québec Inc. | Bourassa Boyer Inc. |
| CyberGrants | National Bank | 9122 2182 Québec Inc. | Bright Funds |
| Daily Seafood Inc. | Financial Markets | 9165-1083 Québec Inc./ | Brivia Group Inc. |
| Davies Ward Phillips | P&R Desjardins | Chevalier Séguin Group | Bryan Ventures Incorporated |
| & Vineberg | Construction Inc. | 9384-9610 Québec Inc. | Bucan |
| Federal Real Estate | Pierre & Camille Dupuis Inc. | 9480-3418 Quebec Inc. | C3F Télécom Inc. |
| Foodtastic | PricewaterhouseCoopers LLP | 9825754 Canada Inc. | CAE |
| GardaWorld | Purkinje Inc. | Abundance Canada | Calgary Foundation |
| Genatec Inc. | S3 Technologies | | |

› Canada Hydraulic Equipment	› Delcap	› Gestion Deloitte S.E.C	› Ken and Roma Lett Foundation
› Canada ICI Capital Corporation	› Dentons Canada	› Gestion Francois Beaudoin Inc.	› Kodem
› Canaropa	› Denise and Robert Gibelieu Foundation	› Gestion Gauthier Lépine Inc.	› KPMG MSLP
› Caprea Real Estate Experts	› Deux Mille Foundation	› Gestion Jean-Guy Marier Inc.	› KRBLawyers
› Carrousel Packaging	› D.D.R. Machining Inc.	› Gestion Luc Rodrigue (2019) Inc.	› Laboratoire Mag Québec Inc.
› Cercle Filles d'Isabelle # 715	› Développement Immobilier Deva6	› Gestion M. Côté Inc.	› La Fondation du Grand Montréal
› Charbonneau	› DL Professional Corporation	› Gestion Raymond Brodeur Inc.	› La Fondation Jean-Luc Gravel et Brigitte Breton
› Chagall	› Dre Xuan Linh Chi Ho. Optometrist	› Gestion Rosaire G. Dubé Inc.	› Letko Brosseau
› Chiasson Gauvreau Inc.	› Duprop Investments Ltd.	› Gestion S.M.B Inc.	› Lohn Foundation
› Chimp Foundation-Charitable Impact Foundation	› Énergir	› GETPAQ Inc.	› Loyal Express
› Claude Legault Financial Services	› Enterprise Holdings Foundation	› Glencore Canada	› L'effet Futé
› Clockaudio North America Inc.	› Ercon Welding Inc.	› Groupe Focus	› L'Ébénisterie l'Art Chic Construction Cha-Ric
› Club de l'Âge d'Or de Sainte-Claire	› Famille Brière Foundation	› Groupe Molesini	› Lallemand Inc.
› CO7 Technologies Inc.	› Famille Pageau Fund	› Groupe Regard	› Linea P International Inc.
› Collision St-Charles	› Fidelity Investments Canada ULC	› Heather Waddell Foundation	› Maçonnerie GY Inc.
› Construction CPB Inc.	› Fiera Real Estate	› HUB International	› Mackenzie Investments
› Coop Hydro-Québec	› Forage	› HVAC Inc.	› Mallette LLP
› Corporation Lyand	› Francoise Forest Foundation	› Immo Andre Lesperance Inc.	› Matco Packaging Inc.
› Crawford MacLeod Foundation	› Franklin Templeton Investments	› Investissements Russell	› Mazars, LLP
› Crofton Moore	› Gabriel Aubé Inc.	› Invesco Canada LTD	› MC Finance
› CSINTRANS Inc.	› Gardium Security Inc.	› ITI Hydraulik	› Merck Canada
› D.B. Crook Accounting Prof. Corp.	› Gascon	› Jean-Luc Gravel and Brigitte Breton Foundation	› MERCURE Conseil
› Darche solution Relève	› Génome Québec	› Jenaco	› Michel Rhéaume Investissement Ltée
› De Grandpre Chait LLP	› Gestion Bert Inc.	› JG & KB Scott Foundation	› Millenium Agents Manufacturiers Inc.
	› Gestion Cholab	› Juliette Choiniere and Jean-Denis Gagné Fund	› Missionary Oblates Sisters of Saint Boniface
	› Gestion David Proulx Inc.		

- › MNP
- › Mongeau Pellerin & Co
- › Montreal Metro Development Corporation
- › Nam Polymers Inc.
- › NATIONAL Public Relations
- › Newall Family Foundation Trust
- › Northstone Group
- › Norton Rose Fulbright Canada
- › Nulook
- › Océan
- › Oeuvres Caritatives des Filles de Jésus, Canada
- › OEC Group
- › Parade Leasing
- › Patrick Morin Inc.
- › Paquette & Associés
- › Pertinence Media Inc.
- › PIMCO Canada Corp.
- › Plastiques Forget Inc.
- › Polar Bear
- › Presse Cafe
- › Procolor St-Georges
- › Quincaillerie Demers Inc.
- › R.M. Specialty Cars Inc.
- › Reinsurance Group of Canada
- › Regal Poultry 2017
- › Régulvar Inc.
- › Reliance Construction of Canada Ltd.
- › Robinson Sheppard Shapiro s.e.n.c.r.l./LLP
- › Roland Beaulieu Foundation
- › Roland-Lepage Philanthropic Fund
- › Rosetown Farming Co. Ltd.
- › Roynat
- › Rush Hour
- › Russell Fund
- › Russell Investments
- › Sahara Foundation
- › Saint-Arneault Inc.
- › Sanimax SAN Inc.
- › Sefina Industries Ltd
- › Servantes De Notre-Dame Reine Du Clergé
- › Sister Servants of the Holy Heart of Mary
- › Sisters of Charity of Saint-Louis
- › Sisters of Saint Marcellina
- › Sisters of the Institute of Jeanne D'Arc
- › Signalisation de Montréal Inc.
- › Solutions Avantages Collectifs
- › Solutions Serafin
- › Sollio Cooperative Group
- › Sphere Media Inc.
- › Sun Life Global Investments
- › Telesystem Ltd
- › Thibault Sanchez
- › The DP Martin Family Foundation
- › The Esther and Bernard Besner Family Foundation
- › The Ken and Roma Lett Foundation
- › The P. Austin Family Foundation
- › The Sahara Foundation
- › Timex Realty Corp.
- › Toulon Development Corporation
- › Transfab Magnetic Solutions Inc.
- › Transport Maran Inc.
- › TREZ Capital
- › Trudel
- › United Way of Greater Toronto
- › United Way of Kingston, Frontenac, Lennox & Addington
- › United Way of the Lower Mainland
- › V SPEC TECHNO Inc.
- › Ventilabec
- › Videoville Showtime/VVS Films
- › Voysis
- › White Powder Coating Ltd.
- › White Star Software
- › Wyalta Resources Ltd
- › Zone3 Inc.

Thanks to you,
every
advancement
becomes possible.

OUR **AMBITION** FOR THE FUTURE

For nearly 80 years, CRS has been at the forefront of funding cancer research in Canada. Through renewed strategies and innovative partnerships, we continually adapt our programs to meet the current and future challenges of research.

Our targeted and diverse initiatives support projects that bring hope in cancer prevention, detection, and treatment. This mobilization of our donors and partners allows us to push the boundaries of science and make a tangible impact. Our ambition for the future is to pursue this mission with boldness and innovation, so that each contribution helps us better outsmart cancer.





Charitable Registration
No.119153229RR001

ISSN 1920-8995 – Legal Deposit –
Bibliothèque nationale du Québec, 2024

Montreal

625, President-Kennedy Avenue
Suite 402
Montreal (Quebec)
H3A 3S5

Ottawa

P.O. 4613, Station E
Ottawa (Ontario)
K1S 1P7

Phone: 514 861-9227
Toll-free number: 1 866 343-2262
Email: info@src-crs.ca

CancerResearchSociety.ca

